<DOC>
	<DOCNO>NCT00167882</DOCNO>
	<brief_summary>The purpose study determine influence different 5-aminosalicylate concentration metabolism azathioprine 6-mercaptopurine patient inflammatory bowel disease .</brief_summary>
	<brief_title>The Influence 5–Aminosalicylates Thiopurine Metabolite Levels</brief_title>
	<detailed_description>Background : The concomitant use 5-aminosalicylates ( 5ASA ) next azathioprine ( AZA ) 6-mercaptopurine ( 6MP ) treatment inflammatory bowel disease ( IBD ) may lead increase effectiveness therapy high level active metabolite AZA/6MP ( 6-thioguaninenucleotides ( 6TGNs ) measure . Objectives : To determine influence 5-ASA compound metabolites metabolite AZA/6MP ( 6TGNs + 6-methylmercaptopurine ( 6MMP ) . Methods : Patients quiescent disease AZA/6MP therapy eligible . Patients receive three succeed regime ( 5ASA 2 gram/5ASA 4 gram/ 5ASA ) 4 week next standard AZA/6MP therapy . At start end every regime 5ASA major metabolite ( N-acetyl-5ASA ) determine serum next measurement 6TGNs 6MMP erythrocyte . The safety monitor standard laboratory parameter every four week . Population : Patients IBD remission unchanged AZA/6MP dosage least 4 week . Medication : 5ASA ( Pentasa ® granule ; Ferring ) administer orally dosages 2 4 gram daily period 4 week . Endpoints : The rise decrease 6TGNs 6MMP different 5ASA regime . The evaluation safety co-administrating 5ASA next AZA/6MP . Risks : Side effect 5ASA use limit well know . Some case report describe potential risk develop myelodepression AZA/6MP 5ASA give together due rise 6TGNs . However , daily practice drug administer together frequently . The risk frequent blood draw minimal usually self-limiting ( haematoma ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Adult patient , age 18 – 70 year Informed consent Diagnosis CD UC least 6 month ( histological endoscopically confirm ) Steady state AZA 6MP use ( unchanged thiopurine regime least 4 week ) Normal liver kidney function ( ALAT / AP / creatinin &lt; 2 x upper normal limit ) Quiescent disease ( HBI score ≤ 4 CD modify TLWI score ≤ 4 UC ) Bone marrow suppression ( platelet / leucocytes &lt; 1 x low normal level ) Presence active infection ( fever CRP &gt; 1 x upper normal limit ) Anemia ( hemoglobin &lt; 6 mmol ) Known duodenal Crohn ’ disease interfere significantly resorptive area Small bowel surgery interfere significantly resorptive area Known intolerance 5ASA compound Current use 5ASA compound Use 5ASA compound within last 30 day Concomitant use allopurinol , ACEinhibitors furosemide Pregnancy , expect pregnancy lactation within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Inflammatory bowel disease</keyword>
	<keyword>azathioprine</keyword>
	<keyword>6-mercaptopurine</keyword>
	<keyword>5-aminosalicylate</keyword>
	<keyword>metabolism</keyword>
</DOC>